The insider selling is routine in scale and follows a typical post-earnings pattern of option exercises and liquidity sales. The CMO's $3.70M sale is the largest, but at 0.06% of market cap it is not material. Monitor for any additional insider sales in the next 30 days; if the selling accelerates to >0.5% of market cap, it would warrant a more bearish reassessment. The strong Q2 results and $284.2M cash position support the neutral read.
Price Chart
Executive Summary
Two Liquidia insiders — the Chief Medical Officer and a Director — sold a combined $5.03M in open-market stock over three days, with the CMO alone selling $3.70M. The sales follow the company's Q2 2026 earnings release 14 days ago, which showed strong revenue growth and profitability but an EPS miss. The total sales represent approximately 0.08% of the company's $6.3B market cap, which is below the 0.1% materiality threshold, making this cluster routine in scale despite the C-suite involvement. The CMO's sale is likely liquidity-driven post-vesting, and the Director's sale follows option exercises, consistent with non-informative insider selling patterns.
Key Financial Metrics
Key Facts
- Chief Medical Officer Rajeev Saggar sold 50,000 shares at $74.06 for $3.70M on 2026-08-19.
- Director Katherine Rielly-Gauvin sold 18,393 shares at $72.23 for $1.33M on 2026-08-20.
- Chief Business Officer Jason Adair exercised multiple derivative tranches and sold 73,631 shares total for $5.09M on 2026-08-21.
- Total open-market sales by all insiders in the cluster: ~$5.03M, representing ~0.08% of LQDA's $6.3B market cap.
- Sales occurred 14 days after LQDA reported Q2 2026 net product sales of $170.4M (+31% QoQ) and net income of $74.7M, but EPS of $0.74 missed consensus of $0.84.
- No open-market purchases were made by any insider in the cluster.
Financial Impact
Total insider sales of ~$5.03M, or ~0.08% of market cap — well below the 0.1% materiality threshold for insider clusters.
Risk Factors
- Patent litigation with United Therapeutics seeking injunctive relief remains an unresolved overhang.
- EPS miss of $0.74 vs $0.84 consensus could pressure the stock if growth decelerates.
- Insider selling, while routine in scale, could accelerate if the stock continues to trade near $70+ levels.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-LQDA-1787728412689 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 13, 2026 13d ago | 8-K | $33.94 $34.78 | ▲ +2.48% | ▲ +2.19% | $43.74 (+28.87%) |
Oct 13, 2026 13d ago | Insider Cluster | $33.94 $34.78 | ▲ +2.48% | ▲ +2.19% | $43.74 (+28.87%) |
Sep 30, 2026 26d ago | 8-K | $27.99 $28.64 | ▼ −2.32% | ▼ −1.58% | $43.74 (−56.27%) |
Sep 3, 2026 7w ago | 8-K | $68.63 $68.66 | ▲ +0.04% | ▲ +0.43% | $43.74 (−36.27%) |
Sep 3, 2026 7w ago | Press Release | $68.63 $68.66 | ▲ +0.04% | ▲ +0.43% | $43.74 (−36.27%) |
Aug 25, 2026 8w ago | Insider Cluster | $71.36 $69.94 | ▼ −1.99% | ▼ −2.65% | $43.74 (−38.71%) |
Aug 21, 2026 9w ago | Insider Cluster | $70.27 $70.49 | ▲ +0.31% | ▼ −0.01% | $43.74 (−37.75%) |
Aug 12, 2026 10w ago | 8-K | $78.79 $72.10 | ▼ −8.49% | ▼ −9.19% | $43.74 (−44.49%) |
Aug 12, 2026 10w ago | Press Release | $78.79 $72.10 | ▲ +8.49% | ▲ +9.19% | $43.74 (+44.49%) |
Jul 29, 2026 12w ago | Insider Cluster | $86.80 $84.11 | ▼ −3.10% | ▼ −3.82% | $43.74 (−49.61%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers